A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

By G. Raghu, K. Brown, W. Bradford, K. Starko, P. Noble, David A. Schwartz, T. King. New England Journal of Medicine, 2004

608 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/637d83b2c88167464362ce7073618f8090b611f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. T. King

In Pulmonary and Respiratory Medicine

1. G. Raghu
2. P. Noble
3. T. King
4. Brigham C. Willis
5. Z. Borok
6. TA Wynn

Citations in the corpus

• Interstitial lung disease guideline (2008, background): “Nagai S., Kitaichi M., Hamada K. et al. Hospital based historical cohort study of 234 histologically proven Japanese patients with IPF.”
• Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. (2005, background): “26,27 With regard to specific effects on lung epithelial cells, TGF-(cid:2) 1 has been noted to down-regulate surfactant protein and RNA production and to increase extracellular matrix component production in cultured AECs.”
• The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis (2005, methodology): “Overview Using data from a recently completed clinical trial (3), we performed a series of exploratory analyses of physiologic variables, dyspnea measures, hospitalizations, and characteristics of mortality in patients randomly assigned to receive placebo.”
• Pirfenidone in idiopathic pulmonary fibrosis (2009, background): “In cases AFFILIATIONS *Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, #Dept of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, "Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, +Fourth Dept of Internal Medi”
• Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity (2005, unknown): “Interferon-c is poorly effective in IPF [ 25 ], causes emphysema in mice [26], and thus is not advisable in CPFE.”
• Interstitial lung disease in systemic sclerosis: a simple staging system. (2008, methodology): “Mortality, disease progression (‘‘time to decline’’ in either FVC levels of >10% from baseline or DLCO levels of >15% from baseline) and ‘‘progression-free survival’’ were quantified from the date of HRCT, as previously described (10, 13 ) (see online supplement).”
• Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. (2005, background): “In a recent study, there appeared to be significant episodes of acute respiratory decompensations preceding death in patients with progressive IPF (6).”